News

On August 19, 2022, Porton Advanced Solutions (Porton Advanced) announced the completion of its Series B financing round with over US$80Million. Current round of financing was led by…
Read More...

Bristol Myers Squibb announced that it has successfully completed its acquisition of Turning Point Therapeutics, Inc. (“Turning Point”), in an all-cash transaction. With the completion…
Read More...

Astellas Pharma Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the company's New Drug Application (NDA) for fezolinetant, an investigational oral,…
Read More...

Atomwise announced that it has established a strategic and exclusive research collaboration with Sanofi that will leverage its AtomNet platform for computational discovery and research…
Read More...

Celltrion Healthcare announced that the European Commission (EC) has approved Vegzelma (CT-P16), a biosimilar bevacizumab referencing EU-approved Avastin, for the treatment of…
Read More...

Nuance Pharma announces the Center for Drug Evaluation has approved its Investigational New Drug application supporting its pivotal clinical trial of Ensifentrine for the maintenance…
Read More...

Valneva SE announces that it has initiated rolling submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of the Company’s…
Read More...

Novavax, Inc. announced that New Zealand's Medsafe has granted expanded provisional approval for Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine for active immunization to prevent coronavirus…
Read More...

bluebird bio, Inc. announced the U.S. Food and Drug Administration (FDA) has approved ZYNTEGLO (betibeglogene autotemcel), also known as beti-cel, a one-time gene therapy…
Read More...

WuXi STA, a leading Contract Research, Development, and Manufacturing Organization (CRDMO), is pleased to announce the groundbreaking for its new 190-acre pharmaceutical manufacturing…
Read More...

AGC Biologics announced a strategic partnership with RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cells (hMSCs), highly engineered media, and bioprocess…
Read More...

Roche announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) for Polivy (polatuzumab vedotin-piiq) in…
Read More...

Bridge Biotherapeutics, a South Korean clinical-stage biotechnology company developing novel drugs for cancer, fibrosis and inflammation, announced it has received notice from the U.S.…
Read More...

Mitsubishi Tanabe Pharma America, Inc. announced the publication of a paper entitled, "Intravenous edaravone treatment in ALS and survival: an exploratory, retrospective, administrative…
Read More...

Gilead Sciences, Inc. announced an agreement with Everest Medicines to transfer all development and commercialization rights to Gilead for Trodelvy (sacituzumab govitecan) in Greater…
Read More...

Merck, known as MSD outside the United States and Canada, and Orna Therapeutics, a biotechnology company pioneering a new investigational class of engineered circular RNA (oRNA)…
Read More...

Catalent, Inc. announced that it has reached an agreement to acquire Metrics Contract Services (Metrics), a full-service specialty Contract Development and Manufacturing Organization…
Read More...

Evotec SE  and Alpine Immune Sciences, Inc. announced that Evotec’s Seattle-based subsidiary, Just – Evotec Biologics, Inc., expanded a multi-year partnership with Alpine for the…
Read More...

aTyr Pharma, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted the company Fast Track designation for its lead therapeutic candidate, efzofitimod (ATYR1923),…
Read More...

TRON Group, Inc. and Nanopharmaceutics, Inc. ("Nano"), a privately-held clinical-stage pharmaceutical development company incorporated in Florida, announced today the signing of a…
Read More...